Phytoestrogen compositions and associated methods

Abstract

Methods for controlling estrogen metabolite formation in a subject and compositions for use therein are disclosed and described. In one aspect, estrogen metabolite formation may be controlled by coadministering an effective amount of a phytoestrogen and an indole compound.

What is claimed is: 
     
         1 . A method of controlling estrogen metabolite formation in a subject comprising:
 co-administering an effective amount of a phytoestrogen with an effective amount of an indole compound, in order to synergistically increase 2-hydroxyestrone production as compared to 2-hydroxestrone production attained by administration of either the phytoestrogen or the indole compound alone.   
     
     
         2 . The method of  claim 1 , wherein the indole compound is a member selected from the group consisting of: indole-3-carbinol, indoleacetic acid, indolebutyric acid, indolmycin, 3-indolylacetone, indomethacin, and indoramin. 
     
     
         3 . The method of  claim 2 , wherein the indole compound is indole-3-carbinol. 
     
     
         4 . The method of  claim 1 , wherein the phytoestrogen is a plant derived compounds having a diphenolic structure resembling the structure of a synthetic estrogen. 
     
     
         5 . The method of  claim 4 , wherein the phytoestrogen is an isoflavone. 
     
     
         6 . The method of  claim 5 , wherein the isoflavone is a member selected from the group consisting of: genistein, diadzein, equol. 
     
     
         7 . The method of  claim 6 , wherein the isoflavone is genistein. 
     
     
         8 . The method of  claim 4 , wherein the phytoestrogen is a glycoside. 
     
     
         9 . The method of  claim 1 , wherein the phytoestrogen is genistein, and the indole compound is indole-3-carbinol. 
     
     
         10 . An estrogen metabolite controlling composition comprising:
 a synergistically effective amount of an indole compound and a phytoestrogen compound, said compounds present in amounts sufficient to affect the estrogen metabolism by increasing metabolic production of a 2-hydroxyestrone metabolite.   
     
     
         11 . The composition of  claim 10 , wherein the indole compound is a member selected from the group consisting of: indole-3-carbinol, indoleacetic acid, indolebutyric acid, indolmycin, 3-indolylacetone, indomethacin, and indoramin. 
     
     
         12 . The composition of  claim 11 , wherein the indole compound is indole-3-carbinol. 
     
     
         13 . The composition of  claim 10 , wherein the phytoestrogen is a plant derived compounds having a diphenolic structure resembling the structure of a synthetic estrogen. 
     
     
         14 . The composition of  claim 13 , wherein the phytoestrogen is an isoflavone. 
     
     
         15 . The composition of  claim 14 , wherein the isoflavone is a member selected from the group consisting of: genistein, diadzein, equol. 
     
     
         16 . The composition of  claim 15 , wherein the isoflavone is genistein. 
     
     
         17 . The composition of  claim 13 , wherein the phytoestrogen is a glycoside. 
     
     
         18 . The composition of  claim 10 , wherein the phytoestrogen is genistein, and the indole compound is indole-3-carbinol. 
     
     
         19 . The composition of  claim 10 , further comprising a pharmaceutically acceptable carrier. 
     
     
         20 . A method of synergistically biasing estrogen metabolism in a subject toward production of a 2-hydroxyestrone metabolite comprising:
 administering to a subject an effective amount of an indole compound and an effective amount of a phytoestrogen.